Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. - Wikidata - wikimedia - TriplyDB

Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.

Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.

http://www.wikidata.org/entity/Q48483797

about

The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study Application of cross-species PET imaging to assess neurotransmitter release in brain Cerebral 5-HT release correlates with [(11)C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain The relationship between reward and punishment processing and the 5-HT1A receptor as shown by PET.Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.(11)C-CUMI-101, a PET radioligand, behaves as a serotonin 1A receptor antagonist and also binds to α(1) adrenoceptors in brain.PET tracers for serotonin receptors and their applications Dopamine modulates reward-related vigor Molecular imaging as a guide for the treatment of central nervous system disorders Social brains on drugs: tools for neuromodulation in social neuroscience.Presynaptic Serotoninergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study.Optimising PET approaches to measuring 5-HT release in human brain.Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain.Test-retest reliability of [11C]AZ10419369 binding to 5-HT(1B) receptors in human brain.Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT1A [11C]CUMI-101 PET and Functional MRI Study.Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study.Serotoninergic effects on judgments and social learning of trustworthiness.Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study.The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram.Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain.

P2860

Q23992160-358E2A31-1AF4-4730-8BA3-25326FFA7AD2 Q26865012-DC7DCD68-E242-40EF-9EFF-00D00823048B Q30303267-F55601E1-8B81-49B4-99DA-C777DC839F5E Q33755322-9923C8E5-3F94-484B-A539-DEFA6A718364 Q34214169-D5CE6E02-957C-4524-9822-29725CDA2101 Q34583782-5BBF1A08-A7DE-49B9-8272-F790D4D06E16 Q35090637-281FE8A4-DB97-495B-964E-08A285AC9287 Q36927746-5387B6A5-D07D-4B9D-B47C-A5850BEFD1C2 Q37262953-5E57B761-2E6B-418D-9330-D70C7B2D51DF Q37535877-3E9097A9-6165-45B1-A017-EAC70709CB07 Q37661822-DD761148-7922-4E3A-9893-72F4FBF32393 Q38531787-D0C51A9B-E0FA-426F-9975-8CE283EB0D67 Q39005986-7C96B3E8-5E13-4787-9B21-FAC23CBE9E37 Q44425348-4305A4DE-F265-410D-BD6F-86989FF1212D Q45059253-0EE61257-2040-46F3-B64B-0E60C463C71D Q46526889-4ADCB66B-BC31-4AB1-BF4B-26D4D3D14606 Q48336652-85F0055F-E492-4C97-A567-755518E70333 Q48364109-4C7A89B7-172A-4755-99E7-BB1A62CAC3C6 Q48554423-E49F9356-6FA5-468B-8D80-934D98C88E45 Q50152811-3F451A05-A7E2-46B6-82F9-CF3E2542A501 Q50561917-A77A119C-516D-49FB-B0F7-7D1A5C360CCB Q55711478-46A162E9-589F-466F-A0F4-6D67B12B7301

P2860

Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.

http://www.wikidata.org/entity/Q48483797

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Measuring endogenous changes i ...... ]CUMI-101 PET challenge study.

@en

Measuring endogenous changes i ...... ]CUMI-101 PET challenge study.

@nl

type

label

Measuring endogenous changes i ...... ]CUMI-101 PET challenge study.

@en

Measuring endogenous changes i ...... ]CUMI-101 PET challenge study.

@nl

prefLabel

Measuring endogenous changes i ...... ]CUMI-101 PET challenge study.

@en

Measuring endogenous changes i ...... ]CUMI-101 PET challenge study.

@nl

P1433

Q48483797-3C80F7AA-A9AB-466E-A635-639656EDF115

P1476

Q48483797-D2AB66FB-3A99-4274-B99B-1A326650ECE7

P2093

Q48483797-45BF3F3B-4ED0-4456-A5CF-C6EA5A77844A

Q48483797-5B085B22-9D59-41A6-B7B3-E44A44E07DD0

Q48483797-F7A0476C-C54C-429C-B93D-BCA22087A604

P2860

Q48483797-0401C1D6-38E5-48D0-9D7E-A56CC847FACB

Q48483797-04976139-BD35-4112-87E6-116FBDB9D97F

Q48483797-0FBE0029-FFE2-471F-B690-AEEF5F8BE2F4

Q48483797-13C4E1DA-C5AB-4E31-BD96-74BC2F2B16F8

Q48483797-199A4475-19E6-4833-BDA7-B968A49BD3FD

Q48483797-1A0DCBFB-BF3C-403E-9F78-2F16B052381C

Q48483797-24BDAF50-BBD6-42A9-B689-5101B3E433E8

Q48483797-285CB6E1-D9AA-4219-A4E4-18714A93E1BD

Q48483797-28C889D2-7CDE-4B3C-B8C8-EAA6A9D3FA78

Q48483797-2B8D6393-96A3-4193-B230-FFD6301A0E93

P2888

Q48483797-9F4005E4-6CED-4C9C-B9B6-EB3409D4E8A0

P304

Q48483797-4D2585FA-79A0-497B-9BB6-5B5B86FBEC7D

P31

Q48483797-D10A7779-4CB2-47AB-A720-FCEAAA660E46

P356

Q48483797-F2B7BD1F-908D-409D-A585-30F897450185

P407

Q48483797-4964E7C6-625C-4AB6-8AC5-3DAFC9316C83

P433

Q48483797-C7E69528-FEE9-492E-8206-9F690B5BED5D

P478

Q48483797-C70C5B81-ABE4-452C-81C8-D1D128628865

P50

Q48483797-3071AFEF-DCCF-48B9-98F7-CAF9CCA91526

Q48483797-4130E867-8B4D-453C-A736-2C96271AF552

Q48483797-62DAC7BF-E406-4C23-A502-B13283E87C9C

Q48483797-C4D6CAE2-A754-43B2-BB11-2A2A27326BE2

Q48483797-D6D9C1E2-FBB8-4550-A617-7564E9B0DD18

Q48483797-DFBA947B-DD61-4B6D-ADA6-CC192DA5180B

P577

Q48483797-CAA3D899-646E-408C-B232-029F3B42C105

P5875

Q48483797-F1C27C95-F6C6-4C9F-98C3-A541FA0CC6AB

P698

Q48483797-E0561033-49B9-4888-8ECE-1EE9A85A3AF9

P356

P1433

Molecular Psychiatry

P1476

Measuring endogenous changes i ...... C]CUMI-101 PET challenge study

@en

P2093

J P Roiser

http://www.w3.org/2001/XMLSchema#string

L Rosso

http://www.w3.org/2001/XMLSchema#string

P Faulkner

http://www.w3.org/2001/XMLSchema#string

P2860

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET

A review of central 5-HT receptors and their function

Antidepressants and the risk of suicidal behaviors.

Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

The human raphe nuclei and the serotonergic system.

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer.

Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality.

P2888

P304

1254-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MP.2012.78

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Federico Turkheimer

Sudhakar Selvaraj

Philip J. Cowen

Elias Mouchlianitis

P577

2012-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225186265

http://www.w3.org/2001/XMLSchema#string

P698

22665264

http://www.w3.org/2001/XMLSchema#string